AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 251 min read$CLBT

GEE DAVID NICHOLAS sold $49K of CLBT

GEE DAVID NICHOLAS (Chief Marketing Officer) sold 4,323 shares of Cellebrite DI Ltd. (CLBT) at $11.36 on 2026-08-24 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · GEE DAVID NICHOLAS
Published Aug 25, 2026, 8:09 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 25, 2026, 8:37 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$CLBT
Neutral
high confidence
Mentioned
$CLBT
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLBTNeutralLow
01

Why it matters

The disclosed sale is routine and does not alter the company's fundamentals

02

Market read

Minor insider sell; unlikely to affect CLBT price or sector sentiment

03

What to watch

Potential upcoming product launch or contract not disclosed

Relevance 2/10Novelty 4/10Timing: post‑market 2026‑08‑24

Background

Form 4 filings disclose insider trades; investors monitor for material changes

Company-level read

Ticker impact

$CLBTNeutralHigh confidence
Context

Chief Marketing Officer sold 4,323 shares for $49,111 via a 10b5-1 plan

Expected impact

No significant impact

Evidence & confidence

Sale size is small relative to total holdings and market cap; typical pre‑arranged sale

Market effects

Sector

None; Cellebrite operates in digital forensics niche

Regional

No broader regional effect

Global

Limited to investors tracking insider activity

Counterpoint

What could challenge this read

Sale could signal insider confidence if holdings remain sizable

Key entities

  • Company
    Cellebrite DI Ltd.

    Provider of digital intelligence solutions, ticker CLBT

  • Person
    GEE DAVID NICHOLAS

    Chief Marketing Officer of Cellebrite

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CLBT insider trading history →

Related articles

AUG 20
$CLBTMedAI 8/10

Cellebrite (CLBT) Q2 2026 Earnings Call Transcript

Cellebrite (CLBT) announced Shiv Ramji as its new CEO, replacing Tom Hogan. The company missed Q2 revenue expectations due to delayed large transactions and lower-than-expected ARR uplift. Despite this, they raised their full-year adjusted EBITDA target. Ramji outlined plans to improve sales execution and forecasting discipline. The company sees growth in new products and federal business, with a 25% increase in Defense and Intelligence ARR.

yahoo.com3 min
AUG 16
$CLBTMedAI 8/10

Why Cellebrite DI (CLBT) Is Down 30.4% After Cutting 2026 Outlook And Announcing CEO Transition

Cellebrite DI Ltd. reported half-year 2026 results and cut its full-year revenue outlook to US$555 million to US$561 million, implying 17% to 18% growth. The company also announced a CEO transition, with Shiven Ramji succeeding Thomas E. Hogan. The guidance reduction, weaker profitability, and delayed large government contracts contributed to a sharp stock drop.

simplywall.st6 min
AUG 15
$CLBTMedAI 8/10

Cellebrite DI Ltd. Q2 2026 Earnings Call Summary

Cellebrite DI Ltd. reported Q2 2026 results below expectations, citing delayed large transactions and procurement hurdles tied to foreign entity status. Full-year ARR guidance was cut to $550m–$560m, while adjusted EBITDA was raised to $153m–$159m. Management said Insights installed base reached 65% and Genesis launched with $400k ARR.

yahoo.com6 min